Nafamostat Mesilate for Prevention of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis: A Prospective, Randomized, Double-Blind, Controlled Trial

Objectives: Pancreatitis is the most common major complication of endoscopic retrograde cholangiopancreatography (ERCP). Efforts have been made to identify pharmacologic agents capable of reducing its incidence and severity. The aim of this trial was to determine whether prophylactic nafamostat mesilate, a synthetic protease inhibitor, would reduce the frequency and severity of post-ERCP pancreatitis. Methods: A total of 286 patients were randomized to receive either intravenous nafamostat mesilate or placebo 60 minutes before ERCP and for 6 hours after ERCP. A database was prospectively collected by a defined protocol. Standardized criteria were used to diagnose and grade the severity of pancreatitis. Results: The groups were similar with regard to patient demographics and to patient and procedure risk factors for pancreatitis. The overall incidence of pancreatitis was 5.9%. It occurred in 4 (2.8%) of 143 patients in the nafamostat group and in 13 (9.1%) of 143 patients in the control group (P = 0.03). Pancreatitis was graded mild in 2.1% and moderate in 0.7% of the nafamostat group and mild in 7.0% and moderate in 2.1% of the control group. There was no significant difference between the groups in the severity of pancreatitis. Conclusions: Prophylactic intravenous nafamostat mesilate reduces the frequency of post-ERCP pancreatitis.

[1]  Y. Bai,et al.  Glyceryl trinitrate for prevention of pancreatitis after endoscopic retrograde cholangiopancreatography: a meta-analysis of randomized, double-blind, placebo-controlled trials. , 2009, Endoscopy.

[2]  P. Andersen,et al.  Meta‐analysis: nitroglycerin for prevention of post‐ERCP pancreatitis , 2009, Alimentary pharmacology & therapeutics.

[3]  G. Kim,et al.  Nafamostat mesylate in the prevention of post-ERCP pancreatitis and risk factors for post-ERCP pancreatitis. , 2009, Gastrointestinal endoscopy.

[4]  B. Yoo,et al.  The Prophylactic Effect of Somatostatin on Post-Therapeutic Endoscopic Retrograde Cholangiopancreatography Pancreatitis: A Randomized, Multicenter Controlled Trial , 2008, Pancreas.

[5]  K. Lee,et al.  Preventive Effects of Ulinastatin on Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis in High-Risk Patients: A Prospective, Randomized, Placebo-Controlled Trial , 2008, Pancreas.

[6]  P. Higgins,et al.  A meta-analysis of rectal NSAIDs in the prevention of post-ERCP pancreatitis , 2008, Gut.

[7]  M. Freeman.  Pancreatic stents for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[8]  F. Lee,et al.  Action of antiproteases on the inflammatory response in acute pancreatitis. , 2007, JOP : Journal of the pancreas.

[9]  T. Kawabe,et al.  Antiproteases in preventing post-ERCP acute pancreatitis. , 2007, JOP : Journal of the pancreas.

[10]  G. Porro,et al.  Efficacy of postprocedure administration of gabexate mesylate in the prevention of post-ERCP pancreatitis: a randomized, controlled, multicenter study. , 2007, Gastrointestinal endoscopy.

[11]  A. Andriulli,et al.  Prophylactic administration of somatostatin or gabexate does not prevent pancreatitis after ERCP: an updated meta-analysis. , 2007, Gastrointestinal Endoscopy.

[12]  T. Matsui,et al.  Comparison between ulinastatin and gabexate mesylate for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a prospective, randomized trial , 2007, Journal of Gastroenterology.

[13]  T. Shimosegawa,et al.  Consensus of primary care in acute pancreatitis in Japan. , 2006, World journal of gastroenterology.

[14]  N. Ishimura,et al.  Ulinastatin shows preventive effect on post‐endoscopic retrograde cholangiopancreatography pancreatitis in a multicenter prospective randomized study , 2006, Journal of gastroenterology and hepatology.

[15]  M'hamed Temkit,et al.  Risk Factors for Post-ERCP Pancreatitis: A Prospective Multicenter Study , 2006, The American Journal of Gastroenterology.

[16]  Y. Shiratori,et al.  Ulinastatin for pancreatitis after endoscopic retrograde cholangiopancreatography: a randomized, controlled trial. , 2005, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[17]  B. C. Wong,et al.  Outpatients undergoing therapeutic endoscopic retrograde cholangiopancreatography: Six‐hour versus overnight observation , 2004, Journal of gastroenterology and hepatology.

[18]  A. Andriulli,et al.  Prophylaxis of ERCP-related pancreatitis: a randomized, controlled trial of somatostatin and gabexate mesylate. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[19]  P. Testoni.  Pharmacological prevention of post-ERCP pancreatitis: the facts and the fiction. , 2004, JOP : Journal of the pancreas.

[20]  K. Saigenji,et al.  Efficacy of Continuous Regional Arterial Infusion of a Protease Inhibitor and Antibiotic for Severe Acute Pancreatitis in Patients Admitted to an Intensive Care Unit , 2004, Pancreas.

[21]  Olusola Oiofinlade.  Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography. , 2004, Gastroenterology.

[22]  G. Costamagna,et al.  Comparison of two dosing regimens of gabexate in the prophylaxis of post-ERCP pancreatitis , 2003, American Journal of Gastroenterology.

[23]  M. Nishibori,et al.  Nafamostat mesilate is an extremely potent inhibitor of human tryptase. , 2003, Journal of pharmacological sciences.

[24]  A. Andriulli,et al.  Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: a multicenter, placebo-controlled, randomized clinical trial. , 2002, Gastrointestinal endoscopy.

[25]  T. Keck.  Site-Specific Therapeutic Effects of Protease Inhibitors: Effect of Route of Administration in Experimental Pancreatitis , 2001, Pancreatology.

[26]  T. Keck,et al.  Regional effects of nafamostat, a novel potent protease and complement inhibitor, on severe necrotizing pancreatitis. , 2001, Surgery.

[27]  C. Crosta,et al.  Complications of diagnostic and therapeutic ERCP: a prospective multicenter study , 2001, American Journal of Gastroenterology.

[28]  M. E. Ryan,et al.  Same-day discharge after endoscopic biliary sphincterotomy: observations from a prospective multicenter complication study. The Multicenter Endoscopic Sphincterotomy (MESH) Study Group. , 1999, Gastrointestinal endoscopy.

[29]  S. Fan,et al.  Prophylactic effect of somatostatin on post-ERCP pancreatitis: a randomized controlled trial. , 1999, Gastrointestinal endoscopy.

[30]  A. Mariani,et al.  Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. Gabexate in digestive endoscopy--Italian Group. , 1996, The New England journal of medicine.

[31]  C Liguory,et al.  Endoscopic sphincterotomy complications and their management: an attempt at consensus. , 1991, Gastrointestinal endoscopy.

[32]  S. Fujii,et al.  New synthetic inhibitors of C1r, C1 esterase, thrombin, plasmin, kallikrein and trypsin. , 1981, Biochimica et biophysica acta.

[33]  R. Wensel,et al.  Pancreatic injury following ERCP. Failure of prophylactic benefit of Trasylol. , 1977, Gastrointestinal endoscopy.

[34]  Guang-su Xiong,et al.  Clinical trial of gabexate in the prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis. , 2006, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[35]  M. W. B. E. Klar.  Complications of Pancreatic Surgery and Pancreatitis , 2002 .

[36]  A. Andriulli,et al.  Pharmacologic treatment can prevent pancreatic injury after ERCP: a meta-analysis. , 2000, Gastrointestinal endoscopy.

[37]  T. Sato,et al.  Pharmacological studies of FUT-175, nafamostat mesilate. V. Effects on the pancreatic enzymes and experimental acute pancreatitis in rats. , 1986, Japanese Journal of Pharmacology.